A systematic review and meta-analysis of neuropathic pain associated with COVID-19 (notice n° 1366009)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02551cam a2200217 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518053819.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Di Stefano, G. |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | A systematic review and meta-analysis of neuropathic pain associated with COVID-19 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 6 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Background and objectiveNeuropathic pain is a complication of COVID-19 that has been occasionally reported and has received increased attention in the scientific literature. In this systematic review and meta-analysis, we aimed to provide information on the frequency of neuropathic pain associated with COVID-19.Databases and data treatmentWe systematically reviewed and analyzed literature regarding neuropathic pain associated with COVID-19. Literature searches were conducted in the PubMed, EMBASE, and Cochrane Library databases. We considered prospective and retrospective studies published up until September 2022 (limitations included English language, full-text publications, and studies including at least 10 patients). A random-effects meta-analysis was performed and heterogeneity and publication bias were assessed.ResultsWe identified 149 studies. We included 17 studies in the systematic review, and included 6 studies reporting the frequency of neuropathic pain in the acute/subacute phase of COVID-19 in the meta-analysis. The estimated frequency of neuropathic pain ranged between 0.4 and 25%. Forest plot analysis showed that the random effect overall frequency was 10% (95% CI: 5%–15%), with a high level of heterogeneity (Chi2 = 104; Tau2 = 0.004; df = 5; I2 = 95%; test for overall effect: Z = 3.584; p ConclusionsThe estimated frequency of neuropathic pain associated with COVID-19 should be interpreted with caution due to the high heterogeneity across studies and the lack of clear diagnostic criteria. Significance: Emerging evidence supports the development of neuropathic pain as a complication of COVID-19. However, longitudinal studies that enroll consecutive patients with COVID-19 and establish clear diagnostic criteria for neuropathic pain are needed to better assess the frequency of this condition. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Falco, P. |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Galosi, E. |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Di Pietro, G. |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Leone, C. |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Authier, Nicolas |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Douleur et analgésie | 37 | 3 | 2024-12-06 | p. 181-190 | 1011-288X |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-douleur-et-analgesie-2024-3-page-181?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-douleur-et-analgesie-2024-3-page-181?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux